Ewing's sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response.
2016
Aims The purpose of this study was to review a large cohort of patients
and further assess the correlation between the histological response
to chemotherapy in patients with Ewing’s sarcoma with the overall
(OS) and event-free survival (EFS). Patients and Methods All patients treated for Ewing’s sarcoma between 1980 and 2012
were reviewed. Of these, 293 patients without metastases at the
time of diagnosis and treated with chemotherapy and surgery were
included. Patients were grouped according to the percentage of necrosis
after chemotherapy: Group I: 0% to 50%, Group II: 51% to 99% and Group
III: 100%. Results The mean age at diagnosis was 16 years (1 to 62) and the mean
follow-up was 9.1 years (six months to 32.6 years). The OS and EFS
for the series were 75% and 65% at five years. There were significant
differences in survival between the groups of necrosis: 0% to 50%
(OS: 49% and EFS: 45% at five years, respectively) compared with
51% to 99% (OS: 72% and EFS: 59% at five years, respectively) and
100% (OS: 94% and EFS: 81% at five years, respectively) (p There were no significant differences in survival between patients
treated between 1980 and 1989 compared with those treated between
1990 and 1999, and those treated between 2000 and 2012 (p = 0.55). Conclusion Only patients with 100% necrosis after chemotherapy should be
classified as having a good response to chemotherapy because they
have significantly better rates of survival compared with those
with any viable tumour in the surgical specimen. Cite this article: Bone Joint J 2016;98-B:1138–44.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
25
References
29
Citations
NaN
KQI